Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 16/20 | 0.43 |
| ▸ | CXCR1 | P25024 | 7/20 | 0.43 |
| ▸ | CCR6 | P51684 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12263428 | 0.84 | CCR6 (0.45) | CXCR2CXCR1CCR6 | |
| SCHEMBL17368790 | 0.83 | CCR6 (0.60) | CXCR2CXCR1CCR6 | |
| SCHEMBL12261140 | 0.76 | CXCR2 (0.67) | CXCR2CXCR1CCR6 | |
| SCHEMBL12087250 | 0.75 | CXCR2 (0.58) | CXCR2CXCR1CCR6 | |
| SCHEMBL13406843 | 0.73 | CXCR2 (0.43) | CXCR2CXCR1CCR6 | |
| SCHEMBL12576083 | 0.73 | CXCR2 (0.72) | CXCR2CXCR1CCR6 | |
| SCHEMBL12087066 | 0.72 | GAA (0.52) | CXCR2CXCR1CCR6 | |
| SCHEMBL12576141 | 0.72 | CXCR2 (0.72) | CXCR2CXCR1CCR6 | |
| SCHEMBL12261179 | 0.71 | CXCR2 (0.59) | CXCR2CXCR1CCR6 | |
| SCHEMBL14895045 | 0.71 | CCR6 (0.61) | CXCR2CXCR1CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-12-10 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | CXCR2 7/4885CXCR1 3/4885CCR6 19/4885 |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | CCR1, ACKR3, CXCR1 | CXCR2 7/4885CXCR1 3/4885CCR6 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.